肾细胞癌（RCC）是最常见的肾脏癌症。本研究旨在评估 E-钙粘蛋白的潜在预测价值，E-钙粘蛋白是与肿瘤转移相关的上皮间质转运 (EMT) 过程的标志物。我们检索了 PubMed、Embase 和 Cochrane Library 以识别前瞻性研究。总结风险比 (HR)、比值比 (OR) 和 95% 置信区间 (CI)，以验证 E-钙粘蛋白与生存和临床特征之间的关系。使用 NOS 表评估纳入研究的质量。然后，我们使用R语言和dplyr包分析来自癌症基因组图谱计划（TCGA）数据库的遗传数据和临床特征进行验证。包括21篇文章。分析显示高 E-钙粘蛋白表达与良好预后之间存在密切联系（对于 OS，HR = 0.35，95% CI：0.19-0.62；对于 PFS，HR = 0.19，95% CI：0.03-0.53；对于 DSS，HR = 0.25，95% CI：0.08-0.76；对于 RFS，HR = 0.71，95% CI：0.44-1.16；对于 DFS，HR = 0.28，95% CI：0.13-0.61；对于 T 期，OR = 0.21，95 % CI：0.11-0.41；对于 N 期，OR = 0.07，95% CI：0.02-0.25；对于 M 期，OR = 0.12，95% CI：0.02-0.60；对于临床分期，OR = 0.29，95% CI ：0.18-0.47；对于核级别，OR = 0.23，95% CI：0.13-0.41；对于肿瘤大小，OR = 0.49，95% CI：0.26-0.92）。该研究结果得到了使用 TCGA RCC 患者队列的生物信息学分析的支持（P < 0.01）。根据目前的数据，E-cadherin 可以预测 RCC 患者更好的预后。

Renal cell carcinoma (RCC) is the most common cancer of the kidney. This study aims to evaluate the potential predictive value of E-cadherin, a marker of the epithelial mesenchymal transit (EMT) process that has been associated with tumor metastasis.We searched PubMed, Embase, and Cochrane Library to identify prospective studies. Hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were summarized to validate the relationship between E-cadherin and survival and clinical characteristics. The quality of the included studies was assessed using the NOS table. Then, we analyzed genetic data and clinical characteristics from The Cancer Genome Atlas Program (TCGA) database using R language with the dplyr package for validation.Including 21 articles. The analysis revealed a strong link between high E-cadherin expression and favorable prognosis (for OS, HR = 0.35, 95% CI: 0.19-0.62; for PFS, HR = 0.19, 95% CI: 0.03-0.53; for DSS, HR = 0.25, 95% CI: 0.08-0.76; for RFS, HR = 0.71, 95% CI: 0.44-1.16; for DFS, HR = 0.28, 95% CI: 0.13-0.61; for T stage, OR = 0.21, 95% CI: 0.11-0.41; for N stage, OR = 0.07, 95%CI: 0.02-0.25; for M stage, OR = 0.12, 95% CI: 0.02-0.60; for clinical stage, OR = 0.29, 95% CI: 0.18-0.47; for nuclear grade, OR = 0.23, 95% CI: 0.13-0.41; for tumor size, OR = 0.49, 95% CI: 0.26-0.92). The findings were supported by bioinformatic analysis which used TCGA RCC patient's cohort (P < 0.01).Based on the current data, E-cadherin may predict a better prognosis in RCC patients.